# Doncaster Wound Care Formulary and Associated Pathways and Policies



For use across the Doncaster Wound Care Alliance

- Doncaster Primary Care
- Doncaster NHS SY ICB Doncaster Place
- Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH)
- Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust (DBTH).
- FCMS Doncaster Urgent Treatment Centre (UTC) & GP Out Of Hours service

(This is an interactive document, therefore is not to be printed. This is access via the below link where the most update version will be available: <a href="https://www.dbth.nhs.uk/services/skin-integrity/information-for-healthcare-professionals/doncaster-wound-care-alliance/doncaster-wide-associated-clinical-pathways/">https://www.dbth.nhs.uk/services/skin-integrity/information-for-healthcare-professionals/doncaster-wound-care-alliance/doncaster-wide-associated-clinical-pathways/</a>)

Author/reviewer:						
(this version)	<ul> <li>DBTH</li> <li>Michaela Delahunty, Lead Nurse, Tissue Viability and</li> </ul>					
	Lymphoedema Services – RDaSH					
	Karen Jennison, Senior Medicines Optimisation					
	Technician - NHS SY ICB Doncaster Place					
Date	Written May 2021					
written/revised:	Revised September 2022 and September 2024					
Approved by:	Doncaster Medicines Optimisation Group (MOG)					
	September					
Date of approval:	October 2024					
Date issued:	October 2024					
Next review	This is a living document with updates taken as required					
date:	with updated national recommendations. Minimum					
	review time is every 3 years.					

#### **Contributions to the Doncaster Wound Care Alliance include:**

Organisation	Job Title / Department
NHS SY ICB Doncaster Place	Lead Commissioner Finance Lead Chief Pharmacist Locality Lead Pharmacist
Doncaster and Bassetlaw Teaching Hospitals	The Skin Integrity Team Communication and Media Graphic Designer Clinical Specialist – Procurement
FCMS	Service Lead
Primary Care Doncaster	Chief Executive Doncaster Provider Alliance Lead Chief Nurse Contracts Manager Projects Coordinator Finance Lead
Rotherham Doncaster and South Humber NHS Foundation Trust	Doncaster Care Group Director Service Manager The Tissue Viability and Lymphoedema Service The Podiatry Foot Protection Service Continuous Service Improvement Manager Finance Lead
Additional Support	Lead Nurse - Sheffield Adults Burns Unit Burns Care Nurse Advisor - Sheffield Children's Hospital Community Practice Teacher - RDaSH Vascular Nurse Specialist – DBTH Service Manager Planned and Unplanned Community Nursing Service

#### **Amendment Form:**

Version	Date Issued	Brief Summary of Changes	Author
Version 3.1	November	<ul> <li>Added Leukomed sorbact and T skin sensitive range as was missed off the update</li> </ul>	Kelly Phillips
Version 3	Ocotber 2024	<ul> <li>Contents page amended</li> <li>Product list amended to categories with specification and images</li> <li>Contingency plan for products</li> <li>Rational, reason or evidence for product selection</li> <li>Product information links</li> <li>Lay out of the pathways</li> <li>Updates to all pathways to ensure they are in line with updated national recommendations and evidence</li> </ul>	Kelly Phillips
Version 2	September 2022	<ul> <li>Contents page amended</li> <li>Product list amended to include 2<sup>nd</sup> line products</li> <li>New pathways for leg ulcers and foot ulcers added</li> </ul>	Kelly Moore

#### CONTENT Section Page No **Introduction** 4 5 2 <u>Purpose</u> 5 3 **Duties and Responsibility** 3.1 **Education** 5 3.2 **Direct Wound Care Provisions** 6 3.3 Off Formulary Prescribing 6 **Wound Care Alliance meeting** 3.4 6 3.5 **Formulary Review** 6 4 7 <u>Procedure</u> 4.1 **Holistic Wound Assessment** 7 4.2 8 4.3 **Documentation and Photography** 8 9 4.4 **Antimicrobial Guidance** 4.5 **Diabetic Foot Guidance** 9 **Compression Guidance** 4.6 10 5 **Pathway and Products** 11 5.1 **Associated Pathways and Policies** 11 5.2 **Predicated Variability** 12 5.3 **Products for use** 13 Absorbents - Super absorber non adhesive dressing Adhesive island wound dressing

	Adhesive island wound dressing	
	Adhesive remover	
	<u>Alginates</u>	
	<u>Antimicrobials</u>	
	<u>Bandages</u>	
	<u>Compression Bandages – Lower Limb</u>	
	Compression – Lower Limb Hosiery and Wraps (Sizes and ordering number as per Appendix 7)	
	Compression Hosiery applicators	
	<u>Debridement</u>	
	De-sloughing dressing	
	<u>Dermal Gel Pad</u>	
	<u>Film</u>	
	Film Island dressing	
	<u>Fludroxycortide</u>	
	<u>Foam (Adhesive Boarder)</u>	
	Foam (featuring TLC)	
	Foam (featuring TLC-NOSF)	
	<u>Hydrocolloids</u>	
	<u>Hydrogel</u>	
	Irrigation and cleansing	
	Low Adherent dressing	
	Negative Pressure Wound Therapy	
	Odour control	
	<u>Post-operative dressing</u>	
	Skin Protection	
	<u>Skin Protection – Incontinence and Moisture</u>	
	Zinc Dressing	
	Wound Contact dressings	
	<u>Tier 4 Products</u>	
	References and Formulary changes tracker 2024	40
<u></u>	Doncaster Wound care Formulary and Associated Pathway and Polices Navigation Flowchart	43
	nent. Do not print the whole document to ensure you access the lastest information and guidance. You care Formulary and Associated Pathway and Polices Navigation Flowchart so you have access to the releva	

#### 1. INTRODUCTION


The Doncaster Wound Care Alliance appreciates the role that a joint wound care formulary and associated pathways and policies play to assist health practitioners in providing safe effective and economic products to service to people living with and at risk of developing a wound. It is important that any new or amended products are introduced in conjunction with the lead clinicians, Medicine Management and the Procurement Teams across the Doncaster Wound Care Alliance. This policy applies to all staff that provide wound care that are employed by one of the organisations within the Doncaster Wound Care Alliance:

- Primary Care Doncaster
- NHS Doncaster NHS SY ICB Doncaster Place
- Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
- Rotherham Doncaster and South Humber NHS Foundation Trust
- FCMS Doncaster Urgent Treatment Centre (UTC) & GP Out Of Hours service

The Wound Care Formulary and Associated Pathways is an interactive document aimed at increasing accessibility and saving CO2e through being paper free. Therefore thought the document you will find hyperlinks to navigate you to other document, websites or sections of this document:

If you see a QR code this indicates it will take you to a relevant document or website with supporting information. Either use you camera phone to access the QR code or hover over the icon and press ctrl + click.	
If you see a blue/purple underlined part of the text this indicates it will take you to a relevant document or website with supporting information.	Wound Bed Preparation Pathway
If you see a house this indicates it will take you back to the content page	

Since 2021 when The Wound Care Formulary and Associated Pathways was launched and became interactive, combining several documents we have saved on average 10,298.7 sheets of paper which equated to 617.922kg CO2e. 617.922kg CO2e equates to 2648 miles travelling by car. With the CO2e saved we could travel to Mersin in Turkey.



## 2. PURPOSE

The purpose of this formulary is to provide clear, understandable guidance on the processes to follow when caring for people living with or at risk of developing a wound. To ensure consistency and evidenced based care across the Doncaster Wound Care Alliance with evidence based assessments, prevention and management of patients at risk of wounds and/or with wounds.

A wound care formulary is a clinical and financial necessity <sup>1</sup>. The wound care formulary is developed by a multidisciplinary team to include a range of clinical and cost-effective products, to serve the patients wound requirements. The formulary is based on a wide range of clinical evidence and peer reviews, with the products being selected on the current clinical evidence and cost considerations. The formulary is balanced with the need for education to underpin the use of the formulary and the wound products included, to ensure that appropriate care is provided. The Doncaster Wound Care Alliance includes a universal structured competency based educational programme for health practitioners providing care for people living with and at risk of developing a wound, to ensure a consistent and cohesive approach for wound care interventions is provided that reflects the current evidence, local policy and pathways, whilst incorporating the national agenda.

#### 3. DUTIES AND RESPONSIBILITIES



#### 3.1 Education

This formulary is for the use of health practitioners who have completed the relevant educational modules to provide direct assessment, prevention and management of wounds in line with the Tier provider across the Doncaster Wound Care Alliance. Choosing a wound management plan depends greatly on a holistic assessment of the patient and their wound; the patient should be at the centre of all care decisions made. The complexity of the wound is divided over 4 tiers.

It is expected that providers of this service will ensure their clinical staff are trained and skilled to the standards set out in the Doncaster Wound Care Pathways and Doncaster Wound Care Training Programme, bespoke to the tiers. The structured educational programme will provide assurance that all staff across Doncaster engaged in wound care interventions are providing a consistent and cohesive approach.

Clinicians providing wound care under the remit of the service must undergo a three yearly update of the Doncaster Wound Care Alliance Education Programme or equivalent approved training. In delegating any element of a wound care plan to non-registered roles within the healthcare delivery team, it is the responsibility of the provider to ensure that the appropriate competency, supervision, indemnity and insurance is in place, and that patient consent is duly sought and recorded. Declarations of assurance to this effect will be required as part of signing up to this specification.

- Tier 1 acute healing wounds, less than 14 days old with healthy granulation/epithelial tissue, managed by the General Practice/ District Nurse / Ward Staff
- Tier 2 chronic healing wounds, more than 14 days old with 50% or more healthy granulation/epithelial tissue, managed by the General Practice/ District Nurse / Ward Staff
- Tier 2 LL chronic healing leg ulcer that have had a comprehensive lower limb assessment and diagnosis
  within a Tier 3 or 4 service previously, with more than 14 days old with 50% or more healthy
  granulation/epithelial tissue, and managed by the General Practice/ District Nurse / Ward Staff
- Tier 3 non healing wounds, 50% or more devitalised/slough/necrotic tissue, managed by the General Practice/ District Nurse / Ward Staff AND a specialist service e.g. The Skin Integrity Team, Tissue Viability and Lymphoedema Service, Vascular Service, Podiatry.

 Tier 4 – Complex non healing wounds, 50% or more devitalised/slough/necrotic tissue, managed by a specialist service only e.g. The Skin Integrity Team, Tissue Viability and Lymphoedema Service, Vascular Service, Podiatry.

The wound care tier module for Doncaster is:



The modules within each tier of the Doncaster Wound Care Alliance and the alignment to the notational frameworks are:

Tier 1



Tier 2 and 2LL



Tier 3



#### 3.2 Direct Wound Care Provisions

General Practitioners (GP's) will receive requests for wound care product perceptions, however the direct wound care intervention need to be undertaken by the healthcare professional that has completed the Wound Care Alliance Education Modules. Do not exceed a 14 day supply of dressings and products at any one time, unless the patient has a long term conservative plan in place where there will be no change to the products required.

#### 3.3 Off formulary prescribing

Where a community tier 4 specialist service has exhausted all options of the formulary and request a specific treatment or product for a patient they will provide communication with the GP via letter for an off formulary product to be prescribed. Where secondary care Tier 4 specialist service has exhausted all options of the formulary and request a specific treatment or product for a patient they will provide communication with the Inventory Management and Procurement Department for a specialist request for an off formulary product to be ordered.

#### 3.4 Wound Care Alliance Meeting

Representatives of the Doncaster Wound Care Alliance meet on a bi-monthly basis to review any KPI's or actions for the Wound Care Formulary and the Doncaster Wound Care Alliance.

#### 3.5 Formulary review

A Doncaster wide wound care formulary representative meeting is held Bi- monthly to review any new product, evidence, research that requires review for consideration or any existing products or process that have raised concerns or issue that need re review. The meeting consists of representatives from:

- The Skin Integrity Team
- The Tissue Viability and Lymphoedema Service
- The Podiatry Foot Protection Service
- Procurement at Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
- Procurement at Rotherham and Doncaster and South Humber NHS Foundation Trust
- Procurement at the NHS Supply Chain.

Any suggestions of new products, available new evidence or any concerns are to be submitted to either the Skin Integrity Team, Tissue Viability and Lymphoedema Service or Podiatry Foot Protection Service to enable discussion and review at a Doncaster wide wound care formulary representative meeting:

- The Skin Integrity Team. Tel: 01302 642439. Email: dbth.skinintegrityteam@nhs.net
- The Tissue Viability and Lymphoedema Service Tel via SPA 01302 566999 Email doncaster.spa@nhs.net
- The Podiatry Foot Protection Service 03000 211 550. Email: Rdash.podiatryreferrals@nhs.net

The lead representatives will review and discuss the information presented and identify if there are benefit to the Doncaster Wide Wound Care Formulary or not, taking in into consideration the following points:

- Evidence based practice
- Patient outcomes
- Sustainability
- Net zero carbon emissions.
- Service provisions
- Procurement
- Costings

#### Sustainability and Net Zero:

NHS England established a target to becoming net Zero by 2040 for the emissions the NHS controls directly with an ambition for an 80% reduction by 2036.

Doncaster and Bassetlaw Teaching Hospital NHS Foundation Trust has committed to support delivery the set objectives laid out by the Health and care act 2022 climate change.

As a trust, we are asking suppliers to support this commitment and work with them to achieve a standard that adheres to social value outcomes on ethics, labour and the environmental risk but also mitigating that risk by providing a good quality product that does not affect the outcome for the patient.

#### 4. PROCEDURE



The formulary provides guidance on the processes to follow when caring for people living with or at risk of developing a wound.

#### 4.1 Holistic Wound Assessment

A systematic approach to holistic wound assessment is essential for the delivery of high quality care. A holistic wound assessment considers the 'whole' patient and should comprise of a generic wound assessment minimum data

set<sup>1</sup>. A holistic wound assessment has the potential to:

- Identify factors that require intervention and indicate objectives for management
- Guide appropriate patient and wound management
- Improve healing rates
- Reduce the physical, emotional and socioeconomic impact of wounds on patients
- Benefit practitioners and the NHS by reducing the overall burden of wounds, potentially decreasing workload and the costs associated with wound care
- Raise practitioner and patient morale by improving patient outcomes.

A holistic wound assessment should be performed by a healthcare professional with sufficient knowledge and skills and they should be given sufficient time to perform a holistic wound assessment <sup>3</sup>.

#### **Best practice Statement - Holistic wound Assessment**



#### 4.2 TIMES

Wounds UK (2018)¹ recommend that a holistic wound assessment includes a generic minimum data set for assessment and documentation. Using a structured approach through a generic holistic wound assessment criteria will underpin the assessment, documentation and practice to facilitate a more consistent approach to wound management and can re-focus services and promote improvements in wound care. Additional assessment parameters may be necessary according to wound type, for example when assessing a wound on the lower limb. This has been compiled using all the criteria from the NHS England Leading Change Adding Value Framework⁴ and the assessment criteria from the SIGN Guideline for Venous Leg Ulcers⁵.

The wound assessment tool recommended to use as part of a holistic wound assessment is T.I.M.E.S. This tool was developed and published in 2003<sup>6</sup> by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation. The T.I.M.E.S acronym facilitates the assessments of:

- Tissue
- Infection, inflammation or biofilm
- Moisture
- Edges of the wound
- Surrounding skin.

## Generic wound assessment minimum data set



## Criteria of T.I.M.E.S and the assessment of associated barriers to wound healing



## Wound bed preparation. TIME in practice



#### 4.3 Documentation and Photography

High standard, consistent documentation can guide objective setting, care planning and evaluation/reassessment<sup>1</sup>. Documentation of a holistic wound assessment and a management plan should take place at each dressing change including each parameter in the generic wound assessment minimum data set. The reviews should determine whether the patient and the wound are improving, deteriorating or unchanged; checking the progress against the objectives of management<sup>1</sup>. Any adjustments to the management plan should be fully documented. Drawings and/or photography can illustrate the wound, aiding the assessment. If photography is used, local photography guidance and polices should be adhered to at all times. Only take photographs when consent has been given and according to local guidelines (which may include who is permitted to take photographs and require that camera users are registered)<sup>7</sup>. The National Wound Care Strategy Programme (NWCSP) provides recommendations on photography, however ensure that local Trust/organisation photography guidance is adhered to:

Top Tips for Photography



NWCSP Photography recommendation



#### 4.4 Antimicrobial Guidance

Evidence concerning the efficacy of topical antimicrobial agents in the management of wounds remains equivocal<sup>8</sup>. Reports of resistance to antimicrobial agents are limited but misuse of these products must be avoided. Managing wound infection is costly for the patient and to the health economy, and a structured approach to assessment and management of the patient as well as correct use of antimicrobials is essential to ensure safe, effective and personcentred care<sup>9</sup>. Antimicrobials including silver dressings should be used in an appropriate and structured manner for limited periods with clear clinical treatment objectives.

Best practice recommendations for the appropriate use of silver dressings suggest a 'Two-week challenge' where the efficacy of silver dressings can be assessed<sup>10</sup>. Use should be based on an accurate and detailed holistic assessment and then monitored and controlled. Therefore it is recommended that antimicrobial agents are used in accordance with the Pathway for Wound Infection with a review of the antimicrobial agent requirements undertaken after two weeks<sup>8</sup> (as a minimum).

Making the case for cost effective wound management



Wound Infection Institute Consensus 2022



EWMA Antimicrobials and nonhealing wounds: An update



#### 4.5 Diabetic Foot Guidance

For successful treatment of Diabetic Foot Ulcers (DFU) it is essential that an assessment is undertaken to

determine the underlying causative factors, and where possible, the cause removed or modified. DFU's are commonly neuropathic or ischaemic, however, they can be a mix of both and are often complicated by comorbidities and lifestyle factors such as Hyperlipidaemia, Obesity, Cardiovascular Disease, Chronic Kidney Disease, tobacco smoking, minimal physical activity and poor glycaemic control.

Diabetic patients with foot ulcers within Doncaster should be referred to the Podiatry Foot Protection Service at Cantley Health Centre for assessment as per Doncaster diabetic guidelines, unless presenting with critical limb ischaemia and/ or spreading systemic infection where urgent referral to vascular/ hospital admission is required. The Podiatry Foot Protection Service is for all patients with diabetic foot complications requiring treatments such as regular debridement, wound care, offloading and insole therapy.

#### **Neuropathic or Ischaemic**



#### 4.6 Compression Guidance

Compression is used to manage conditions associated with chronic venous insufficiency, including post-thrombotic syndrome, varicose veins, venous eczema, lipodermatosclerosis, and swelling in the legs associated with pregnancy<sup>11</sup>. It is also effective as part of an integrated, multifaceted approach to managing lower limb wounds and oedema, as it has been demonstrated to help improve skin integrity, restore limb shape and enhance patient quality of life<sup>12</sup>. Compression options vary in degrees of compression, fabric, stiffness, size, length, and whether they are closed or open-toe. For example hosiery kits, hosiery, wraps and bandages. They exert the greatest degree of compression at the ankle, and the level of compression gradually decreases up the leg<sup>13</sup>.

A full Lower Limb Assessment (see Lower Limb Assessment Pathway and Appendix 1,2 and 3), including an Ankle Brachial Pressure Index reading should be completed prior to compression being applied<sup>2</sup>. Compression should continue for as long as there is evidence of venous disease – in most cases this is life-long (exc. pregnancy). Many brands of compression garments and bandages are available. The recommended degree of compression and compression garment or bandage type needed depends on the condition being treated. The healthcare professional completing the Lower Limb Assessment will indicate the most suitable product based on the assessment in line with Appendix 2. Please note all requirements for flat knit garments must be reviewed and assessed by TVALS prior to ordering.

Made to measure compression garments should only be selected if the patient has had their leg measurements checked in the past six months and none of the standard sizes are appropriate. Patients treated with compression hosiery should be reviewed every 3, 6 or 12 months depending on their risk factors<sup>14</sup> (Appendix 3 provides guidance on this). Compression hosiery for the sole prevention of DVT for travellers is not available on NHS prescription and patients should be advised to purchase class 1 below knee stockings or proprietary "flight socks".

#### **NICE compression stockings**



### 5. PATHWAYS AND PRODUCTS

Clinical pathways are a common component in the quest to improve the quality of health<sup>15</sup>. Clinical pathways aim to enhance the quality of care by guideing the user through the evidence based decision-making, translating clinical practice recommendations into clinical processes, which in turn will:

- Shorten the duration of the process with faster diagnosis
- Increase coherence of care between different professionals provides
- Reduce the risk of opposing opinions and therapies
- Avoid duplication
- Increase the opportunity for patient empowerment
- Reducing the risk of errors
- Enable cost effectiveness
- Increasing job satisfaction.

All associated pathways and policies can be found in section 5.1. To open the associated pathway (PDF), double click on the paper icon in the PDF link column. The PDF will open in a separate screen. Follow the Aetiology of wounds pathways section first. If there is not a pathway relevant for the wound type you require, follow the Optimisation of wound pathways section.

NB: Only prescibe and provide a 14 day supply of dressings and products unless the patient has a long term concernvative plan in place where there will be no change to the products required.

#### 5.1 Associated Pathways and Policies

	Associated Aetiology of wounds pathways
1	Wound Bed Preparation Pathway with associated Prontosan System Ulcer Guide
2	Pathway for larval debridement therapy
3	Skin care pathway for moisture associated skin damage.
4	Pressure Ulcer Management
5	Pressure Ulcer Clinical Pathway Secondary Care
6	Prevention of medical device related pressure ulcer (MDRPU) guidance
7	Prevention of Paediatric/Neonatal Medical Device Related Pressure Ulcers (DRPU)
8	POSIE's clinical pathway for malignant/fungating wounds
9	Pathway for medical adhesive related skin injuries (MARSI)
10	Skin Tear Pathway
11	Pathways for pre-tibia lacerations
12	Pathway for well legs
13	Lower leg wound guidance
14	Pathway for the application of safe soft lower leg bandaging technique
15	First to dress lower leg pathway for Emergency Departments
16	Guidance for identifying cellulitis or red legs
17	Pathway for Lower limb Lymphoedema
19	Pathway for limb Haematoma
20	<u>Leg Ulcer Pathway</u>
21	Lower limb assessment pathway (Tier 3, 4 and District Nurses)
22	Foot ulcer diagnosis guidance
23	Foot ulcer pathway
24	<u>Foot ulcer assessment pathway – secondary care</u>
25	Pathway for non-Complex Burns (Adult) and Adult Burn referral Guidance
26	Paediatric Minor Burns Injury Pathway
27	Pathway for Obstetrics, Gynaecology and Breast surgical wounds

Associated Aetiology of wounds pathways					
28	Pathway for Orthopaedic hips and spinal wounds				
29	PICO and negative pressure wound therapy (NPWT) selection guide				
30	Negative pressure wound therapy (NPWT) ordering, collecting and returning pathway – secondary care				
31	Pathway for external fixation and pin site care				

Associated Optimisation of wounds pathways				
32	T.I.M.E.S Pathway			
33	Pathway for Wound Infection			

	Associated Policies
Α	Pathway for discharge communications for patients living with wounds
В	Pathway for Patient with Wounds and Complex Lives
С	Appendix 1 – Lower Limb Assessment Criteria (Tier 3, 4 and District Nurses)
D	Appendix 2 - Compression options following lower limb assessment
E	Appendix 3 – Recommended lower limb assessment frequency (Tier 3, 4 and District Nurses)
F	Appendix 4 – Neuropathic and Ischemic Foot Ulcers
G	Appendix 5 – Wound care alliance education programme per Tier
Н	Appendix 6A - Doncaster Wound Care Alliance Learning outcomes for Tier 1  Appendix 6B - Doncaster Wound Care Alliance Learning outcomes for Tier 2 and 2LL  Appendix 6C - Doncaster Wound Care Alliance Learning outcomes for Tier 3
I	Appendix 7 – Compression hosiery and wrap product order list
J	<u>Appendix 8 – Assessment of competency: Practical application of safe soft lower leg bandaging technique</u>
К	Appendix 9 - Assessment of competency: Practice application of compression bandaging: <u>UrgoKTwo</u>
L	Appendix 10 – Assessment of competency: Negative pressure wound therapy
M	Appendix 11 - Assessment of competency: MESI ankle brachial pressure index (ABPI) medical device
N	Appendix 12 – Assessment of competency: Dopplex DMX/DMXR
0	Appendix 13 – GP prescription request form for on formulary dressing/products
Р	Appendix 14 – GP prescription request form for off formulary dressing/products
Q	<u>Appendix 15 – DBTH Discharge with wounds communication and referral form – Form A</u>
R	<u>Appendix 16 – DBTH Discharge with wounds communication and referral form – Form B</u>
S	<u>Appendix 17 – DBTH Discharge with wounds communication and referral form – Form C</u>
Т	Appendix 18 – Wound Care Shared Care Communications Form
U	Appendix 19 - Assessment of competency: Urgo 4 layer system
V	<u>Appendix 20 - Vascular Service - Venous Insufficiency Referral form</u>
W	<u>Appendix 21 - Vascular Service – Peripheral Arterial Disease (PAD) / Chronic Limb</u> <u>Threatening Ischemia Disease Referral Form</u>
X	Appendix 22 - Application guide for Renasys NPWT gauze
Υ	Appendix 23 - Application guide for Renasys NPWT foam

#### 5.2 Predictable variation

If the named product on the pathway is not available a temporary second line product is available to use. This can be found within the section 5.3

#### 5.3 Products for use

Category	adhesive dressing			A super absorber dressing manages high levels of exudate, to maintain skin integrity and support healing by absorbing exudate through the skin contact layer, into the core, which contains superabsorbent polymers where it locks in exudate, bacteria and matrix metalloproteinases. This means the fluid is retained, even under compression.				
Product Name and Image Pathway indicated for use		indicated for	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Kliniderm Superabsorbent		2, 11, 14, 16, 19, 20, 23, 33	7.5 x 7.5cm 10 x 10cm 10 x 20cm 20 x 20cm 20 x 30cm 20 x 40cm	Kerramax	N/A	Green	Evaluation by Skin Integrity Team in comparison with other Superabsorbent non adhesive dressing	
Kerramax  Korramax  Korramax  Korramax  Korramax			Required size	n/a	Only if Kliniderm Superabsorbent is not available through predicted variation	RED	2 <sup>nd</sup> line for predicted variation or Tier 4	
Category	Adhesive island w	ound dressing	Specification	Self-adhesive wou	nd dressing made of a soft no	on-woven fabri	c as support material, with a r	non-adherent wound dressing
Product Na	me and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Cosmopore		23	6 x 7cm 10 x 10cm 10 x 15cm 10 x 20cm	Softpore		Green	Meets Specification	

Softpore			Required size	n/a	Only if Cocmopore is not available through predicted variation	RED	2 <sup>nd</sup> line for predicted variation or Tier 4	
Category	Adhesive re	emover	Specification	Non-sting 2	100% silicone medical adhesive	e remover that	t does not cause skin trauma an	d evaporates in seconds.
Product Nar	me and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Brava adhesive remo	oval spray	Throughout	75ml	Please choose the most cost- effective product available	Adhesive remover that lessens the chance of trauma on the skin by allowing easy removal of the baseplate and any leftover residue.	Green	Meets specification	
Category	Alginat		Specification	Storilo non wovon	alginate fibre dressing or Enzyl	ma Alginagal		
	me and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Kaltostat  KALTOSTAT  AND	and the second s	8	7.5 x 12cm 10 x 20cm	Any other alginate sheet product available on the NSHSC	On contact with a bleeding wound, promotes haemostasis.	Green	On contact with a bleeding wound, promotes haemostasis.	
Flaminal Hydro or Fo	arte	8, 19, 31	15g, 50g (50g only in primary/community care)	Each other	1st line where wound filling gel/fibres are required for tracking wounds.	Green	Hydro -Multipurpose products for nil to min exudate = gelling, debriding and antimicrobial Forte - Multipurpose products for moderate to heavy exudate = gelling, debriding and antimicrobial	

Category	Antimicrobials		Specification		me dressings are designed		f bacteria at the wound surface antimicrobial into the wound, o	
Product Na	Product Name and Image Pathy indicate us		Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
		11, 16, 20, 23, 32, 33	10 x 10cm 15 x 20cm	Acticoat flex 3	1st line antimicrobial dressing where the wound bed is visible or there is a cavity	Green	High (4.6) log reduction in biofilms which maintains for seven days. The only TLC-Ag product on the market	
Flaminal Hydro or F	Forte	8, 19, 32	15g, 50g (50g only in primary/community care)	Each other	1st line where wound filling gel/fibres are required for tracking wounds.	Green	Hydro -Multipurpose products for nil to min exudate = gelling, debriding and antimicrobial Forte - Multipurpose products for moderate to heavy exudate = gelling, debriding and antimicrobial	
Also an antimicrobio	al product							
Cutimed Sorbact	Hearth Storbact	4, 33	7 x 9cm pad 2 x 50cm roll/ribbon 5 x 200cm roll/ribbon	AMD Gauze	1st line antimicrobial dressing where wound filling dressing is required.  Not for use under Negative Pressure Wound Therapy (NPWT)	Green	Dialkylcarbamoylchloride The first product to available to binds microbes irreversibly using this technology	
Kerlix AMD		32, X, Y	15 x 17cm (2's) 11.4cm x 3.7cm roll	Cutimed Sorbact - Not for use under Negative Pressure Wound Therapy (NPWT)	1st line antimicrobial dressing wound filling dressing is for NPWT. Gauze impregnated with 0.2% PHMB.	Green	Can be used under Renasys Negative Pressure Wound Therapy (NPWT)	

Activon  Activon  Fube  Activon  Fube  Fube		32	20g tube	Algivon or Medihoney	As part of the Pathway for Wound Infection	Amber - G	100% medical grade Honey 1 <sup>st</sup> line across the South Yorkshire ICS	
Algivon		32	10 x 10cm	Activon or Medihoney	As part of the Pathway for Wound Infection	Amber - G	100% medical grade Honey 1st line across the South Yorkshire ICS	
Medi Honey	METATORY 1/3	Only use if Acticon and Algicon are not available through predicted variation		N/A	Only use if Acticon and Algicon are not available through predicted variation	RED	2 <sup>nd</sup> line for predicted variation or Tier 4 2 <sup>nd</sup> line across the South Yorkshire ICS	
Acticoat Flex 3 and fle	ACTICOAT PLANTED TO THE PLANTED TO T	20, 23, 32	5 x 5 cm 10 x 10cm	UrgoClean Ag	As part of the Foot Ulcer, Leg Ulcer or Infection Pathway, to be reviewed after 14 days unless Tier 4 service specifies differently	RED	High log reduction within 30 minutes when compared to other silver dressings.	
Category	Category Bandages		Specification	a blend of viscose and p skin. May also be used t	oolyester. Used to reduce	the effect of co		b-bandage wadding comprising paedic casting materials on the are achieved when applying
Product Nam	ne and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links

Bandage – Tubular Clinifast	As required	Yellow 10.75cm x 5m Blue 7.5cm x 5m Beige 17cm x 1m	n/a		Green	Meets specification	
Bandage - Sub Wadding Formflex, K – Soft, Cellona	2, 10, 11, 14, 15, 16, 19, 20, 23, 25, 26, 33	Formflex 10cm x 2.7m K – Soft 10cm x 2.7m	K - Soft Formflex		Green	Meets specification  It is the first layer of the K- Four multilayer compression bandage	
formflex 500		Cellona 10cm x 2.7m	K soft	To be commenced by Tier 3, 4 ONLY	Red	system for venous leg ulcers. For Lymphoedema patients as more rigid and structured that Formflex or K-soft	
Bandage - Light support K- lite  K- LITE K-LITE K-L	2, 10, 11, 14, 15, 16, 19, 20, 23, 25, 26, 33	10cm x 4.5m	n/a		Green	It is the second layer of the K-Four multilayer compression bandage system for venous leg ulcers.	
Category Compression Bandag	es – Lower Limb	Specification	To improve vein circula wounds	tion in legs to treat chror	nic oedema and	aid venous return to prevent or	r assist healing for lower limb
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Urgo K Two 40mmHg	20, 21, D, I	10cm at 18 – 25 cm, 10cm at 25 - 32 cm	UrgoKFour		Green	The pressure remains the same for up to 7 days and at all activity levels thanks to both a short stretch as well as a long stretch bandage.  85% of nurses achieve therapeutic levels of compression at first	

Urgo K Two 20mmHg	20, 21, D, I	10cm at 18 – 25 cm, 10cm at 25 - 32 cm	UrgoKFour MINUS THE KO FLEX LAYER		Green	application due to the unique PresSure indicators	
Actico	For patient with Lymphoedema or as instructed by a Tier 4 service	8cm x 6m 10cm x 6m 12cm x 6m	Consult with the Lymphoedema team	For patient with Lymphoedema or as instructed by a Tier 4 service	Amber - G	RCT - 159 patients, 12 centres- Outcomes; ulcer closure 4 LB 68%, CSSB 73%. Mobility deficit did not affect healing with cohesive short stretch bandages	
Urgo K Four	Only if Urgo K Two is not available through predicted variation.	Standard box	N/A	Only if Urgo K Two is not available through predicted variation. Only to use if competent in the application for 4 layer.	Red	2 <sup>nd</sup> line for predicted variation or Tier 4	
Category		Lower Limb Hosiery es and ordering PIP Appendix 7)	Specification	To improve vein circula healing for lower limb v		reat chronic oedema and aid ve	enous return to prevent or assist
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Altipress liner (10mmHg)	10, 16	10 mmHg	As per the requirements to	For use across the whole of Doncaster	Green		<b>a</b>
Altipress 40 Leg Ulcer Kit	20, 21, D, I	40 mmHg	meet the patients and the ulcers needs. You can take	including with in Hospital. Use as per the	Green		
Altifrom	20, 21, D, I	18 -21 mmHg,	additional advise and support from the Tissue Viability and Lymphoedema	manufacturing guidance and/or instructions from the Tissue Viability and	Green	0	

Jobst Leg Ulcer Kit	20, 21, D, I	18 -21 mmHg,	Service at RDaSH	Lymphoedema Service at RDaSH or Skin Integrity Team at DBTH.	Green	
		41 mmHg				
Activa	20, 21, D, I	10mmHg, Class 1 , Class 2		For use in the community or within primary care (not within secondary care) Use as per the manufacturing guidance and/or instructions from the	Amber -G	
Medi Leg Ulcer Kit	20, 21, D, I	18 -21 mmHg, 41 mmHg		Tissue Viability and Lymphoedema Service at RDaSH	Amber –G	
Actilymph	20, 21, D, I	Class 1, Class 2			Amber –G	

			1		
Sigvaris Comfort	20, 21, D, I	Class 1, Class 2		Amber –G	
Mediven Plus	20, 21, D, I	Class 1 , Class 2		Amber –G	
Jobst Bellavar	20, 21, D, I	Class 1 , Class 2		Amber –G	
Jobst Opaque	20, 21, D, I	Class 1 , Class 2		Amber –G	
Juzo Wraps ACS Calf and Foot	20, 21, D, I	As provided 40mmHg		Amber –G	•
Juxta Cures Calf and Foot	20, 21, D, I	As provided 40mmHg		Amber -G	

Medi Easy Wrap Calf and Foot	20, 21, D, I	As provided 40mmHg
Jobst Farrow Wrap Lite/ Strong	20, 21, D, I	20 - 30 mmHg, 30 - 40 mmHg
Medi Juxta Lite Wrap	20, 21, D, I	As provided 40mmHg
Medi Juxta Cures Wrap	20, 21, D, I	As provided 40mmHg

- Prescribe 2 garments per limb.
- If the patient required made to measure Hosiery please refer to TVALS.
- If there are no changes in the Lower Limb Assessment then 2 garments per limb should last 6 months.
- If the wear time is not lasting the frequency then please refer to TVALS.

Category	Compression Hosiery	applicators	Category	To assist with the applic	cation of compression hos	siery to aid self	-management	
Product Nam	e and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Actiglide		20, 21, D, I	One size L&R	n/a	Must have compression hosiery – Primary/community care only	Amber –G	To assist with the application of compression hosiery to aid selfmanagement	•
Rolly		20, 21, D, I	One size Sigvaris	n/a		Amber –G		
Ezy- As (with or witho	ut handles)	20, 21, D, I	One size	n/a		Amber -G		
Category	Debrider		Specification	sterile, pre-moistened,	single-use cloth for woun	d debridement	-to-reach and undermined wou and cleansing of the surroundi	ng area.
Product Nam		Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Prontosan Debrideme	ent Pad	1, 4, 5, 6, 7, 8, 15, 16, 17, 18, 19, 20,22, 24, 25, 30, 32, 33 X, Y	3 pack 10 pack	Gain advise from the Skin Integrity Team		Green	•	

UCS debridement wip	nes .	To be commenced by Tier 4 or District Nurses ONLY	10 pack	Prontosan Debridement Pad	To be commenced by Tier 4 or District Nurses ONLY	Amber -G		
Category	De-sloughing	dressing	Specification	Polyabsorbent fibres in	the dressing pad provide	a complete and	d continuous cleaning action to	remove slough and exudate.
Product Nam		Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
UrgoClean Ag  Pod - Compresse - Kongresse	Ag - Congress	11, 20, 23, 32, 33	6 x 6 cm, 10 x 10cm 15 x 20cm	Cutimed Sorbact	silver ions provide fast and broad- spectrum antimicrobial efficacy, combined cleaning and antimicrobial action to defeat biofilms and prevents reattachment.	Green	High (4.6) log reduction in biofilms which maintains for seven days. Provides complete and continuous cleaning action to the wound. Efficiency proven in real life study with more than 2000 patients.	
Category	Dermal Ge	l Pad	Specification	Dermal Pads are hypoal	lergenic and latex free an	d heln to cushi	on & protect against bruising, i	niury & pressure ulcers.
Product Nam		Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Kerrapro Pessara Medicing Post Stead  Market Stead Company Post Post Post Post Post Post Post Post	Ometine .	6, 7	10 x 10 x 1.2cm 20 x 20 x 1.2cm 50 x 2.5 x 0.3cm Heel Standard Sacrum/Ankle	Any other dermal pad available on NHS upply chain		Green	Pressure ulcer prevention	•
Category	Emollie	nt	Specification	Emollients are moisturis	•	irectly to the sl	kin to soothe and hydrate it. The	ey cover the skin with a
Product Nam	ne and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
	https://mpd.do	oncasterccg.nl	ns.uk/therapeutic	c-sections/13-skin/	132-emollient-and	-barrier-pr	eparations/1321-emol	lients/



Product Name and Image Pathway indicated for use		Specification Size/pack		if predictable restrictions for use Traffic evidence for product					
Clear film  ClearFilm  Soot Autorities that Country 15cm x 20ccre  ClearFilm  ClearFilm  ClearFilm  ClearFilm  Country  ClearFilm  Country  ClearFilm  Country  ClearFilm  Country  Country  ClearFilm  Country  C	*615150 *415101	4, 6, 7	6 x 7cm, 10 x 12cm, 12 x 12 cm, 15 x 20cm	occurred		Green	To prevent shear and friction on intact skin or to secure a different primary dressing in place.		
Leukomed T Skin Sen	sitive	For sensitive skin for prevention, first aid or medical procedures as required	8 x 10 10 x 25	n/a	DBTH Chatfield suite and Dialysis unit	Amber G	Meets specification		

Tegaderm Film	Only if Clear Film is not available through predicted variation.	As required to replace Clear Film sizes		Only if Clear Film is not available through predicted variation.	RED	2 <sup>nd</sup> line for predicted variation or Tier 4	
Category Film Islan	d dressing	Specification	Vapour permeable dress	sing with adhesive and pac	d.		
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Film Island dressing (Rocialle Healthcare)	First aid as required	10 x 10cm, 10 x 20cm	n/a		Green	Meets specification	•
Leukomed T plus skin sensitive	For sensitive skin for first aid or medical procedures as required	8 x 10 10 x 25	n/a	DBTH Chatfield suite and Dialysis unit	Amber G	Meets specification	
Category Fludroxy	cortide	Specification	Fludrovycortide in tane	from with 4mg per cm2			
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Fludroxycortide tape 4mg per cm2  The street of the street	30	7.5 x 20cm, 7.5 x 50cm	n/a	Only in line with the T.I.M.E.S Pathway for the management of over granulation. Ordered via Pharmacy not NHS supply chain.	Amber G	Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions	•

Category	Foam (Adhesiv	e Boarder)	Specification	Conformable, absorben	t polyurethane foam pad	with a vapour-	permeable film backing and a g	entle silicone adhesive border
Product Name a	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Biatain Silicone 3D fit		4, 23, 25, 26, 32	10 x 10cm,, 12.5 x 12.5cm, 15 x 15cm, 17.5 x 17.5cm, 10 x 30cm	Allevyn Life Bordered Foam	Will confum upto 2cm, therefore a wound filler (unless infection is present) is not required if the wound is no deeper than 2 cms.	Green	Silicone based foam that manages exudate whilst reducing exudate pooling thereby reducing the risk of infection and macerated peri-skin.	
Allevyn non – adhesive		For use where the patient has an allergy or sensitivity to adhesive	10 x 10 cm, 10 x 20cm 15 x 15cm, 20 x 20cm	n/a	For use where the patient has an allergy or sensitivity to adhesive or around port sites.	Amber-G	Manages exudate whilst having no silicone present on the dressing.	
Allevyn Life Bordered Fo	am		10.3 x 10.3cm, 12.9 x 12.9cm, 15.4 x 15.4cm		Only if Biatain Silicone 3D Fit is not available through predicted variation.	RED	Silicone based foam that managnes exudate while offering patient comfort and minimising pain on removal.	
Category	Foam (featu	ring TLC)	Specification		ressing featuring TLC (tec		colloid) Healing Matrix that pro	vides a nurturing environment
Product Name a	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
UrgoTul  See Address of Section 11 Section 12 Section 1		9, 10,	8 x 8cm 10 x 10cm 12 x 12cm 15 x 15cm 15 x 20cm	UrgoStart Plus Border	Liipido-colloid provides and maintains a moist environment that promotes the healing process.	Green		•
Category Fo	oam (featuring TLC-I	NOSF)	Specification	0, .	oid with Nano Oligo Sacch	•	LC-NOSF) is a healing matrix rec	luces excess matrix
Product Name a	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links

UrgoStart Plus Border  UrgoStart	4, 11, 20, 23	6 x 6cm, 10 x 10cm, 15 x 20cm	UrgoStart Plus Pad	As below	Green	As below	
UrgoStart Plus Pad	4, 11, 20, 23	8 x 8cm, 10 x 10cm, 13 x 13cm, 15 x 20cm	UrgoStart Plus Border	Polyabsorbent fibre containing soft-adherent TLC-NOSF Healing Matrix that jellifies in contact with wound exudate, reducing MMP levels and restoring balance to close wounds sooner.	Green	MICE 2019 and 2023 medical technology guidance (MTG42) states that evidence supports the case for adopting UrgoStart dressings to treat diabetic foot ulcers and venous leg ulcers.	
Category Hydrocol	lloids	Specification		d dressing with added algi g edges. Mapping grid to		otion, a vapour-permeable film lasurement.	packing and bevelled edge to
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Comfeel Plus	4, 32	10 x 10cm, 15 x 15cm, 15 x 20cm, 20 x 20cm	Comfeel Plus Contour	Autolytic debridement, providing a warm moist environment. Provides protection to intact skin.	Green	Autolytic debridement and skin protection	
Comfeel Plus Contour	4, 32	6 x 8cm, 9 x 11cm	Comfeel Plus	Autolytic debridement, providing a warm moist environment for wound healing.	Green	Autolytic debridement with contour	

DuoDERM  Line of North York  And a Service of		6, 7	10 x 10cm, 15 x 15cm	Comfeel Plus	Autolytic debridement, providing a warm moist environment. Provides protection to intact skin.	Green	Autolytic debridement and skin protection	
Category	Hydrog	el	Specification		hydrate eschar and aid in	•	, ,	e polymers that expand in water
Product Name	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Intasite Gel		4	8g	N/A	Autolytic debridement	Green	Cooling effect, confirmable, providing moist wound healing and autolytic debridement in a gel.	
Intrasite Conformable		4	10 x 10cm	N/A	Autolytic debridement	Green	Cooling effect, confirmable, providing moist wound healing and autolytic debridement in a impregnated gauze	
Hydroclean Plus  Hydroclean Plus  Hydroclean Plus  Hydrocle		To be commenced by Tier 4 or District Nurses ONLY	4cm round, 7.5 x 7.5cm	Comfeel Plus	To be commenced by Tier 4 or District Nurses ONLY	Amber G	Autolytic debridement	
Category	Irrigation and	cleansing	Specification	_			elp prevent infections in acute a (e.g. venous, diabetic or pressu	_
Product Name and Image Pathway indicated for use		Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links	

	T	T	,				<u> </u>
Prontosan Solution (Irrigation Solution)	1, 4, 5, 6, 7, 8, 15, 16, 17, 18, 19, 22, 24, 25, 30, 31, 32, 33, X, Y	40ml 350ml (only in the primary care)	n/a	Wound cleansing to prevent and treat biofilm formation and bacteria burden	Green		
Prontosan Wound Gel X	1, 4, 5, 6, 7, 8,	50g	n/a		Green		
(Cleansing Gel)  Protect and Section Control of Control	15, 16, 17, 18, 19, 22, 24, 25, 30, 31, 32, 33 X, Y	250g (only in the primary care)					
Normasol – Normal Saline	1, 4, 5, 6, 7, 8, 15, 16, 17, 18, 19, 22, 24, 25, 30, 31, 32, 33, X, Y	25ml	n/a	0.9% w/v sodium chloride in purified water, packed in a sachet. Each sachet is sterile, self-contained and disposable resulting in minimal waste and reduced risk of cross contamination.	Green		
Category Low Adherent	dressing	Specification	Highly absorbent, low-a	dherent dressing.			
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Melolite	For use under plaster caster and around fingers only	5x7.5cm 10x7.5cm	N/A	For use under plaster caster and around fingers only	Amber - G	Meets specification	

	e Wound Therapy	Specification					
Product Name and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
PICO 7	27, 28, 29, X, Y	10 x 20cm, 20 x 30cm 10 x 40cm, 15 x 15cm 15 x 20cm, 15 x 30cm 20 x 20cm, 25 x 25cm	PICO 14	To be commenced by Tier 3 and 4 or District Nurses ONLY and be reviewed after 14 days as per	Amber - G		
PICO 14	27, 28, 29, X, Y	10 x 20cm, 20 x 30cm 10 x 40cm, 15 x 15cm 15 x 20cm, 15 x 30cm 20 x 20cm, 25 x 25cm	n/a	To be commenced by Tier 3 and 4 or District Nurses ONLY and be reviewed after 14 days as per	Amber - G		
Renasys F Foam Kit	29, X, Y	Large	Renasys -G Gauze Kit	To be commenced by Tier 4 or District Nurses ONLY  Tier 4 will supply the consumables for Tier 3 Shared Care	RED		
Renasys -F/AB Abdominal Foam Kit	29, X, Y	One size	N/A	- 3 Shareu Care			
Renasys - G Gauze Kit	29, X, Y	Large	Renasys F Foam Kit				
Y-Connector	29, X, Y	One size	N/A				

This is a live document. Do not print the whole document to ensure you access the lastest information and guidance. You can print the Doncaster Wound care Formulary and Associated Pathway and Polices Navigation Flowchart so you have access to the relevant QR codes.

Renasys G 10FR Round Drain		29, X, Y	One size	N/A				
Renasys G 10mm Flat Drain G		29, X, Y	One size	N/A				
Renasys Touch Canister		29, X, Y	300ml, 800ml	N/A				
Category	Odour cont	trol	Specification	Sterile, non-adhesive, n	nultilayer dressing with an	absorbent lay	er, a one-way, water-resistant f	ilm to delay strikethrough to the
						otive propertie	s, an activated charcoal cloth, a	n absorbent pad for comfort and
Product Name and Ir	image	Pathway indicated for use	Size/pack	a water-resistant top la Second line product if predictable variation has		Formulary Traffic Light	s, an activated charcoal cloth, a  Rational, reason or evidence for product selection	n absorbent pad for comfort and  Product information links
Actisorb  Actisorb		indicated for	Size/pack  9.5 x 6.5cm, 19 x 10.5cm	a water-resistant top la Second line product if predictable	yer Information and	Formulary Traffic	Rational, reason or evidence for product	·

Category	Post-operative	e dressing	Specification	Bacteria proof, water p prevent dressing chang	_	vith an absorbe	ent pad. Visibility through the d	ressing is ideal as this can
Product Name	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
OPSITE Post Op Visible		27, 28	10 x 8cm, 15 x 10cm, 20 x 10cm, 25 x 10cm, 30 x 10cm, 35 x 10cm	OPSITE Post Op		Green		
OPSITE Post Op		27, 28		OPSITE Post Op Visable		Green		
Leukomed sorbact		27, 28	4 x 12cm. 4 x 14cm, 5 x 7.2cm, 10x20cm, 10x25cm, 10x30cm, 10x35cm	OPSITE Post Op		Green	•	
Mepilex border post op	dressing	predicted variation	6 x 8cm, 9 x 10cm, 10 x 15cm, 10 x 20cm, 10 x 25cm, 10 x 30cm, 10 x 35cm		Only if OPSITE Post Op Visable and OPSOTE Post Op are not available through predicted variation.	RED	2 <sup>nd</sup> line for predicted variation or Tier 4	
Category	Skin Pro	otection	Specification	Moisturises and protect fluids, adhesive product	ts mildly damaged and int		ng protection from moisture-as ming a waterproof barrier, prev	enting irritation from bodily
Product Name	Product Name and Image Pathway indicated for use		Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links

Medi Derma-S Total Barrier	Film	4, 6, 7, 9	foam applicator 1ml (pack of 5)		For peri wound skin care	Green	Meets the specification	
Medi Derma-S Total Barrier	Cream	4, 6, 7, 9	2g (20 pack) 28g tube		For peri wound skin care 28g Not for Secondary Care 2g Not for Primary Care	Green	Meets the specification	
Sorbaderm Barrier Film		predicted variation	foam applicator 1ml (pack of 5)		Only if Medi derma S is not available through predicted variation	Red	2 <sup>nd</sup> line for predicted variation or Tier 4	
Sorbaderm Barrier Cream		predicted variation	2g (20 pack) 28g tube		Only if Medi derma S is not available through predicted variation	Red	2 <sup>nd</sup> line for predicted variation or Tier 4	
Category	Skin Protection and Moisture	– Incontinence	Specification	an incontinence-associa	nted dermatitis on intact a	and injured skir	to protect against moisture-rela n, and a dimethicone-based skin age moisture-related skin dama	protectant containing
Product Name and		Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Proshield Foam & Spray Incontinence Cleanser  3, 4, 6		3, 4, 6	Proshield Foam & Spray Incontinence Cleanser 235ml		For prevention and management of MASD	Green	Following award winning work completed by DBTH Procurement and Skin Integrity Team	

Proshield PLUS Skin Protectant	3, 4, 6	Proshield PLUS Skin Protectant 115g		For prevention and management of MASD	Green		When on the link click the blue browse youtube button if it appears
Medi Derma Pro Foam and Spray		250g		Only if Proshield is	Red	2 <sup>nd</sup> line for predicted	
O TOURING SPICE		2306		not available through predicted variation	iicu	variation or Tier 4	
Medi Derma Pro Skin Protectant Ointment  – Non Sting		115g		Only if Proshield is	Red	2 <sup>nd</sup> line for predicted variation or Tier 4	
				not available through predicted variation			
Category Wound Contact	t dressings	Specification				size and impregnation of neutr	al triglycerides to prevent
Product Name and Image	Pathway	Size/pack	penetration of granulat Second line product	ion tissue into dressing. P	etrolatum-free Formulary	Rational, reason or	Product information links
Froudt Name and mage	indicated for use		if predictable variation has occurred	restrictions for use	Traffic Light	evidence for product selection	rioduct information files
Atrauman	15, 25, 26	5 x 5cm, 10 x 10cm, 10 x 20cm	Atrauman Silicone		Green	As a non-adherent wound contact layer, it is particularly suitable for preventing the secondary dressing from sticking to the wound bed and for keeping wound edges and surrounding skin supple.	

Atrauman Silicone  Atrauman  Atrauman  Category	Zinc dre	Children only	5 x 5cm, 10 x 10cm, 10 x 20cm		reat chronic eczema and o			ssociated skin conditions and for over under compression therapy
Product Name a	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Viscopaste		To be commenced by Tier 4 ONLY	7.5cm x 6m	Zipzoc	To be commenced by Tier 4 ONLY for the management of chronic eczema/ dermatitis)	Amber - G	Treatment and management venous insufficiency associated skin conditions and for use in dermatology to treat chronic eczema and dermatitis.	
Zipzoc		2 <sup>nd</sup> line for predicted variation or Tier 4	7.5cm x 6m	n/a	2 <sup>nd</sup> line for predicted variation or Tier 4	RED	2 <sup>nd</sup> line for predicted variation or Tier 4	

#### **Tier 4 Products**

Category	Antimicro	bials	Specification				ne level of bacteria at the wound surface but will no ial into the wound, others act upon the bacteria aft	
Product Name	e and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
lodoflex (lodine Cad	lexomer)	To be commenced by a Tier 4 service ONLY	Pad 5g 4 x 6cm 10g 4 x 6cm lodoflex gel 10g 40g	n/a	To be commenced by a Tier 4 service ONLY	RED	https://bnf.nice.org.uk/wound- management/antimicrobial- dressings/iodine-dressings/	
Inadine Systagenix Inadine		To be commenced by a Tier 4 service ONLY following change to BNF guidance	5 x 5cm 9.5 x 9.5cm	Any other Systagenix Inadine product	To be commenced by a Tier 4 service ONLY following change to BNF guidance	RED		
Durofiber Ag		To be commenced by a Tier 4 service ONLY	5 x 5cm 10 x 10cm 15 x 15cm 2 x 45cm	n/a	To be commenced by a Tier 4 service ONLY Where no effect has been seen with UrgoClean Ag	RED	Meets the specification	
Mepilex Border Ag Fu	oam	To be commenced by Podiatry Services ONLY	7 x 7.5cm 10 x 12.5cm 15 x 17.5cm	n/a	To be commenced by Podiatry Services ONLY	RED	Meets the specification	

Askina Calgitrol Pa	ste	To be commenced by Podiatry Services ONLY	15g, 100g	n/a			Meets the specification	•
Flamazine – Sulfadi per 1 gram  FLAMAZINE  F	azine silver 10mg	To be commenced by a Tier 4 service ONLY	50g 250g	N/A	To be commenced by a Tier 4 service ONLY Ordered via Pharmacy not NHS supply chain	RED	Meets the specification	
Category	Absorbents - Supe adhesive o		Specification	the skin contact la	yer, into the core, w	hich contains su	ate, to maintain skin integrity and support healing I perabsorbent polymers where it locks in exudate, b wen under compression.	
Product Nai	ne and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Zetuvit plus  Zetuvit Plus		To be commenced by Podiatry Services ONLY	10 x 10 cm	n/a	To be commenced by Podiatry Services ONLY	RED	Confirmability to feet	
Category	Debriden	nent	Specification				ng of wounds consisting of aseptically produced lar 'A foam spacer piece(s)	vae of Lucillia sericata sealed in a
Product Na	ne and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links

Category	nd	To be commenced by Tier 4 ONLY	2.5 x 4cmBB50 5x 4cmBB100 5 x 6cmBB200 6 x 12cm BB300 10 x 10cm BB400  Specification	n/a Conformable, abso	To be commenced by Tier 4 ONLY	RED	a vapour-permeable film backing and a gentle silico	one adhesive border
Product Name	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Mepilex XT		To be commenced by Podiatry Services ONLY	10 x 11cm	n/a	To be commenced by Podiatry Services ONLY	RED	Confirmability to feet	
Category	Gelling Fib	pers	Specification				omposed of a blend of cellulose-based fibres. Wher we gel sheet. Exudate is locked within the gel dressi	
Product Name	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Durafiber	*   Restriction of the Control of th	To be commenced by Tier 4 ONLY	5x5cm 10x10cm 15x15cm	Kaltostat	To be commenced by Tier 4 ONLY	RED	Meets the specification	

Category	Heel Ba	alm	Specification	Balm containing 259	% Urea			
Product Name	Product Name and Image		Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links
Flexitol Heel Balm co	ntaining 25% Urea	To be commenced by Tier 4 ONLY	To be 40g , 75g Flexit 10% by Tier 4	Flexitol Cream 10%	To be commenced by Tier 4 ONLY  Primary care: Prescribe by brand for 1 month ONLY. (Patients then recommended	Provides a medically proven regime for dry, cracked heels and feet associated with diabetic		
Flexitol Cream 10%  Flexitol 10% Urea Cream			150g	Flexitol Heel Balm 25% urea	to purchase over the counter if effective)	Amber G	anhidrosis. Urea has highly hydrating and moisturising properties. It is a major constituent of the skin's Natural Moisturising Factor (NMF) and is widely distributed within human tissue.	

- Flexitol heel balm (25% urea) is recommended for those people who have severe dry skin with the presence of underlying medical conditions that increase the risk of potential limb loss (such as diabetes, peripheral vascular disease, severe chronic kidney disease, total sensory neuropathy to lower limbs).
- Some long-term conditions such as diabetes lead the individual more prone to dry skin that if not managed may deteriorate and lead to a breach in the skin surface allowing bacterial entry and infection. Those patients who also have lower limb vascular disease and/ or neuropathy are at extremely high risk of amputation and therefore a good skin care regime is essential.
- Diabetic feet are more likely to become dry and callused due to autonomic neuropathy. Urea is a keratolytic which removes dead skin cells, and it is also a humectant which helps hydrate the skin.
- Where necessary patients with Severe/ moderate callus associated with the conditions listed will be advised by the Podiatry Foot Protection Service to request a prescription for 25% Flexitol Heel Balm for 2-4 weeks on an acute prescription. If no improvement or a deterioration seen when reviewed, refer back to Podiatry Foot Protection Service. After 2-4 weeks, if the patient's skin has improved with 25% Flexitol Heel Balm, the patient should then be advised to switch to 10% Flexitol urea cream, most patients should be advised to purchase OTC but there may be patients who will require an ongoing prescription and would be reviewed by the Podiatry Foot Protection Service.

Category Paraffin Gauze Dressings		Specification	•	intains shape, resists fraying. A					
		/ .	sterile paraffin tulle gras dressing made from open weave gauze.						
Product Name and Image Pathway indicated for use		Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links		
Jelonet Tier 4 ENT Surgery ONLY		5 x 5cm, 10 x 10cm	n/a		RED				
Category Paraffin Free Emollient S			Specification	HOFAs product to provides essential fatty acids, in the form of linoleic acid, to the skin's intercellular lipid matrix, mechanically repairing the stratum corneum; helping to increase skin hydration, strengthen the skin barrier and improve elasticity whilst reducing TEWL.					
Product Name	and Image	Pathway indicated for use	Size/pack	Second line product if predictable variation has occurred	Information and restrictions for use	Formulary Traffic Light	Rational, reason or evidence for product selection	Product information links	
Linovera Emulsion		Tier 4	30ml	n/a	As below	RED	As below  DBTH and RDaSH initial evaluation: The evaluations also found that considerably less product was required to cover the same surface area compared to previous practice. The unique formulation of both LV products allowed for easier application and coverage; absorbing into the skin was noted to be much quicker compared to previous used products,		
		Tier 4	50ml	n/a	Tier 4 – whilst evaluations are being completed by DBTH and RDaSH	RED	allowing for the donning of hosiery/compression without delay. LV Oil dispenses 0.06 ml per pump and LV Emulsion dispenses 0.81g per pump, the average pumps needed, as part of this evaluation, for each treatment was 6 for LV Oil (0.36 ml) and 7 for LV Emulsion (5.67g) meaning a full bottle would sufficiently last 83 and 18 applications respectively.		

#### Dermatology chemical compounds, steroids, and any other medication

To be prescribed as recommended by the Dermatology Department in line with Doncaster and Bassetlaw Joint Formulary, for guidance refer to Doncaster and Bassetlaw Joint Formulary on the NHS SY ICB Doncaster Place Medicines Management Website.

http://medicinesmanagement.doncasterccg.nhs.uk/



- 1. Wounds UK (2018) Best Practice Statement: Improving holistic assessment of chronic wounds.
- 2. National Wound Care Strategy Programme (2020) Lower Limb Recommendations for Clinical
- 3. Coleman, S., Nelson, E. A., Vowden, P. et al (2017). Development of A Generic Wound Care Assessment Minimum Data Set. Journal of Tissue Viability. 26 (4) 226-40.
- 4. NHS (2018) Leading Change, Adding Value: A framework for nursing, midwifery and care staff. NHS England
- 5. SIGN (2010) Management of chronic venous leg ulcers. A national clinical guideline. Healthcare Improvement Scotland
- 6. Schultz et al (2003) Wound Bed Preparation. Wound Repair Regeneration. 11 1-28.
- 7. Sperring B, Baker R. (2014) Ten Top Tip. Taking high-quality digital images of wounds. Wounds International. 5 (1) 7-8.
- 8. European Wound Management Association (2013) Position Document: Antimicrobials and non-healing wounds. London: MEP Ltd
- 9. Dowsett (2014) Adopting the 2-week challenge in practice: making the case for silver dressings. Wounds UK. Vol 10 (2).
- 10. International Consensus (2013) Making the Case for Cost-Effective Wound Management
- 11. National Institute for Health and Care Excellence (NICE) (2012) Clinical knowledge summaries: compression stockings
- 12. Osborne K (2009) How to use multilayer inelastic bandaging and compression garments. In: Skills for Practice: Management of chronic oedema in the community. Wounds International
- 13. Nelson, E. A., Rickley, C. V., Dale, J. and Morrison, M. (1996) The management of leg ulcers. Journal of Wound Care. 5: 2, pp 73-6.
- 14. Furlong W (2015) Recommended frequency for ABPi review for patients wearing compression hosiery. British Journal of Nursing, 2015, Vol 24, No 20
- 15. Lawal, A.K., Rotter, T., Kinsman, L. et al. (2016) What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic review. *BMC Med*. 14 (35)

#### References within the clinical pathways:

- International Wound Infection Institute (WII) (2016) Wound Infection in clinical practice. Wounds International.
- Le Blanc K et al. (2018) Best Practice recommendations for the prevention and management of skin tears in aged skin. Wounds International.
- Wounds UK (2020) Best Practice Statement: Management of lower limb skin tears in adults. Wounds UK, London.
- European Pressure Ulcer Advisory Panel (2019) Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline.
- Nichols, E. (2015) Describing a wound. From presentation to healing. Wound Essentials. Vol 10 No 1.
- Harris A, Rolstad BS (1994) Hypergranulation tissue: a non traumatic method of management. Ostomy Wound Manage 40 (5): 20 - 2, 24, 26 - 30.

- Johnson S, (2007) Haelan Tape for the treatment of overgranulation tissue. Wounds UK, Vol 3, no 3, 70 74.
- Wounds UK (2013) Best Practice Statement. Effective exudate management. London.
- Dowsett, C. Bellingeri, A. Carville, K. Garten, A and Woo, K. (2020) A route to more effective infection management: The Infection Management Pathway. Wounds International.
- Beekman, D. proceedings of the Global IAD Expert Panel. (2015) Incontinence Associated Dermatitis: Moving Prevention Forward. Wounds International.
- National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance (2019) Prevention and Treatment of Pressure Ulcers: Quick reference guide.
- NHS Improvement (2018) Pressure ulcers: revised definition and measurement summary and recommendations.
- Jaul, E. (2011) A prospective pilot study of atypical pressure ulcer presentation in a skilled geriatric unit. Ostomy Wound Management. 57(2): 49–54.
- Black, J. (2010)Medical device-related pressure ulcers a call to action. International Journal of Wound Care.
- International Consensus Document (2020) Guideline to the prevention of Medical Adhesive Related Skin Injuries, Journal of Wound care. 29 (3 Suppl 2):S1- S24.
- NICE (2021) Leukomed Sorbact for preventing surgical site infection.
- Furlong W (2015) Recommended frequency for ABPi review for patients wearing compression hosiery. British Journal of Nursing, 2015, Vol 24, No 20.
- McMurray, V. (2003) Managing patients with fungating malignant wounds. Nursing Times. 99(13):55-7.
- National Wound Care Strategy Programme (2021) Draft Surgical Wounds recommendations.
- NICE (2019) PICO negative pressure wound dressings for closed surgical incisions Medical technologies guidance.
- Wounds UK (2020) Best Practice Statement: Post -operative wound care reducing the risk of surgical site infection
- WUWHS Consensus Document. (2018) Surgical Wound Dehiscence improving prevention and outcomes.
- Wounds UK (2017) Assessing a wound for larval debridement therapy.

#### Formulary change tracker 2024

				n.: 1	
Products reviewed	Description	Date	Changes  Added Specifications for all products to	Rational	Outcome
			ensure the product meets the		Specifications for all
Specifications for all products	Specifications for all products	22.7.24		Rational for inclusion	products
					added reason, rational
reason, rational or evidence	reason, rational or evidence		added reason, rational or evidence for	for transparency and supportive	or evidence for each
for each product	for each product	22.7.24	each product	information	product
					added product
					information
Product information	Product information		11.1 1.16 11.16		hyperlink/QR code
hyperlink/QR code where	hyperlink/QR code where	22 7 24	added product information hyperlink/QR code where required/available	, , ,	where
required/available	required/available	22.7.24	code where required/available	information	required/available Added images for
					products (other than
					stockings or wraps as
					the different products
				to help ensure it is the correct product	cant be seen via
Added images for products	Added images for products	22.7.24	Added images for products	that is being ordered/prescribed	photos)
				to ensure other 1st line are used unless	
				there is predictable variation such as	Made 2nd line products
Made 2nd line products red	Made 2nd line products red	22.7.24	Made 2nd line products red	national supply issues	red
				Podiatry surgery specialist tier 4	
ADD Mepilex XT 10x11 and	Walth about a face described			requested a Highly absorbent foam dressing for normal and viscous exudate	
11x20	Highly absorbent foam dressing for normal and viscous exudate	10.6.24	Podiatry tier 4	product	Added to Tier 4 section
IIAZO	normal and viscous exadate	10.0.24	· · · · · · · · · · · · · · · · · · ·	Podiatry surgery specialist tier 4	Added to Tier 4 Section
				requested due to the conformability to	
ADD Zetuvit plus 10x10	Super absorbent pad	10.6.24	Podiatry tier 4	feet	Added to Tier 4 section
CHANGE Honey from					
medihoney to Advancsis				for collaboration across the ICB and	
medical	different supplier	7.6.24	different supplier	local value advantages	different supplier
CHANGE Sorbaderm range					
changed to medi derm S range	different supplier	10.6.24	different supplier	for collaboration across the ICB	different supplier
				not kept in UK ware house anymore by	removed from
Askina Calgitrol AG	Antimicrobial	11.7.24	removed	the company	formulary
				to ensure other 1st line absorbency and	
Durafiber	Gelling Fibers	22.7.24	Tier 4 only	wound filling products are used	Tier 4 only
	made red following latest			1 16 11 1 1 1 1 1 1 1 1 1 1 1 1	
	change to BNF guidance https://bnf.nice.org.uk/wound-			made red following latest change to BNF guidance https://bnf.nice.org.uk/wound-	
	management/antimicrobial-			management/antimicrobial-	
Inadine	dressings/iodine-dressings/	22.7.24		dressings/iodine-dressings/	made red tier 4
	made amber to ensure 1st line				
	are used and this is only			made amber to ensure 1st line are used	
	considered as part of the			and this is only considered as part of the	
Honey (Activon and Algivon)	specific pathway	22.7.24	made amber	specific pathway	made amber
Medi Derma Pro Foam and				Issues over last 18 month with	
Spray	Added as a fine one dock	22.7.24		availability of 1st line product and this	Added as a 2nd line
Medi Derma Pro Skin	Added as a 2nd line product	22.7.24	Added as a 2nd line product RED	was an appropriate alternative  Issues over last 18 month with	product RED
Protectant Ointment – Non				availability of 1st line product and this	Added as a 2nd line
Sting	Added as a 2nd line product	22.7.24		was an appropriate alternative	product RED
ZIP ZOC	Made red	22.7.24	· · · · · · · · · · · · · · · · · · ·	as a 2nd line product	Made red
				The only anti-biofilm silver dressing that	
				provides complete and continuous	
				cleaning action to the wound. Efficiency	
Hara Class As		22.7.24		proven in real-life study with more than	moved to a 1st line
UrgoClean Ag Fludroxycortide tape 4mg per	moved to a 1st line product	22.7.24	·	2,000 patients.  To ensure pathway step 1 and 2 are	product
cm2	made amber	22.7.24	made amber	followed prior to moving to step 3.	made amber
	ac uniber			Following evaluations on the	ac unibel
				effectiveness of the ingrediance being a	
Linovera	added tier 4		added tier 4	replacement for standard emollients	added tier 4

## <u>Doncaster Wound care Formulary and Associated Pathway and Polices Navigation</u> <u>Flowchart</u>

(<u>Link to website: https://www.dbth.nhs.uk/services/skin-integrity/information-for-healthcare-professionals/doncaster-wound-care-alliance/doncaster-wide-associated-clinical-pathways/</u>)














#### Doncaster Wound care Formulary and Associated Pathway and Polices Navigation Flowchart

Work your way down the flow chart to take you to the most relevant pathway. You can either scan the QR code or click on the QR code to open up the pathway.







- Patient in their own home or within a general practice with a non-diabetic/neuropathy/ischemic wound: rdash.tvalsservice@nhs.net
- Patient in their own home or within a general practice with a diabetic/neuropathy/ischemic wound: rdash.podiatryreferrals@nhs.net

#### Other relevant information you may require:

Appendix 15 FORM A Discharged Communications to Tier 1&2 (Secondary Care)	Appendix 16 FORM B Discharged Communications for Tier 3 & 4, DN (Secondary Care)	Appendix 17 FORM C Discharge Communications From Fracture Clinic (Secondary Care)	Appendix 18 Wound Care Shared Care communication form between serviced in the Doncaster Wound Care Alliance	Patients with wounds and Complex Lives	Other useful information around wound healing, barriers to healing and product information)	Well Leg Pathway – following the healing of leg ulceration
	•					

Developed by the Skin Integrity Team July 2024. For review July 2027